Procaps Group SA Market Cap ($113.95 Million)
Market Cap & Net Worth: Procaps Group SA (PROC)
Procaps Group SA market cap. Procaps Group SA (NASDAQ:PROC) has a market capitalization of $113.95 Million ($113.95 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18493 globally and #4320 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Procaps Group SA's stock price $1.10 by its total outstanding shares 112824000 (112.82 Million). Also see cash efficiency ratio of Procaps Group SA for how efficiently the company converts equity into cash flow.
Procaps Group SA Market Cap History (2019–2025)
Procaps Group SA market cap history from 2019 to 2025. Data shows change from $1.11 Billion to $124.11 Million (-32.02% CAGR). Check Procaps Group SA (PROC) share price today for real-time trading data and today's change.
Procaps Group SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Procaps Group SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Procaps Group SA net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.11x
Procaps Group SA's market cap is 1.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.80x
Procaps Group SA's market cap is 8.80 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $1.11 Billion | $324.79 Million | -$17.01 Million | 3.42x | N/A |
| 2020 | $1.17 Billion | $331.47 Million | -$10.45 Million | 3.54x | N/A |
| 2021 | $1.10 Billion | $409.74 Million | -$100.86 Million | 2.68x | N/A |
| 2022 | $592.33 Million | $409.92 Million | $42.54 Million | 1.44x | 13.92x |
| 2023 | $459.19 Million | $414.10 Million | $52.20 Million | 1.11x | 8.80x |
Competitor Companies of PROC by Market Capitalization
Companies near Procaps Group SA in the global market cap rankings as of November 5, 2026. Also see Procaps Group SA assets under control for a full breakdown of the balance sheet.
Key companies related to Procaps Group SA by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Procaps Group SA (2019–2025)
Market capitalization of Procaps Group SA from 2019 to today. Between 2019 and today, Procaps Group SA's market cap moved from $1.11 Billion to $ 124.11 Million, with a yearly change of -32.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $124.11 Million | -52.99% |
| 2024 | $264.01 Million | -42.51% |
| 2023 | $459.19 Million | -22.48% |
| 2022 | $592.33 Million | -46.15% |
| 2021 | $1.10 Billion | -6.25% |
| 2020 | $1.17 Billion | +5.58% |
| 2019 | $1.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 10th, 2026 the market cap of Procaps Group SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $113.95 Million USD |
| MoneyControl | $113.95 Million USD |
| MarketWatch | $113.95 Million USD |
| marketcap.company | $113.95 Million USD |
| Reuters | $113.95 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Procaps Group SA
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use… Read more